Hoth TherapeuticsHOTH
HOTH
About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Employees: 3
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more funds holding
Funds holding: 13 [Q3] → 14 (+1) [Q4]
1.78% less ownership
Funds ownership: 5.31% [Q3] → 3.54% (-1.78%) [Q4]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
43% less capital invested
Capital invested by funds: $322K [Q3] → $182K (-$140K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
267%
upside
Avg. target
$4.50
313%
upside
High target
$5
359%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target | 359%upside $5 | Buy Maintained | 10 Mar 2025 |
HC Wainwright & Co. Raghuram Selvaraju 32% 1-year accuracy 109 / 342 met price target | 267%upside $4 | Buy Reiterated | 23 Jan 2025 |
Financial journalist opinion
Based on 3 articles about HOTH published over the past 30 days
Neutral
PRNewsWire
3 days ago
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as "compassionate use.
Neutral
PRNewsWire
1 week ago
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025 , highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.
Neutral
PRNewsWire
1 week ago
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy Expenditure Hoth is developing this therapeutic in Partnership with the Department of Veterans Affairs Key Findings from the Study: Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet. Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The Company received written notification from Nasdaq on January 23, 2025, stating that because the Company's common stock had a closing bid price at or above $1.00 per share for 10 consecutive business days, from January 7, 2025 to January 22, 2025, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
IP will be used to pursue further indications for HT-001 Cancer Therapeutic NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline. These newly secured patents reflect Hoth's commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the Sequire Investor Summit. To learn more about the Sequire Investor Summit, please visit https://puertorico.srax.com/.
Neutral
PRNewsWire
2 months ago
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt.
Positive
Zacks Investment Research
2 months ago
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
Positive
Benzinga
2 months ago
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?
On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors in cancer patients.
Charts implemented using Lightweight Charts™